Inflammatory bowel disease (IBD), represented primarily by Crohn's disease and ulcerative colitis, comprises chronic inflammatory conditions of the gastrointestinal tract. While not highly prevalent, IBD can generate significant employer costs when not effectively managed, with costs expected to rise due to increasing prevalence, broader biologic use, and earlier diagnosis. This employer action brief outlines leading recommendations to address barriers to timely diagnosis, appropriate treatment, and sustained disease control. It highlights practical, evidence-informed strategies to improve outcomes and reduce avoidable costs through early intervention, appropriate use of advanced therapies, proactive care coordination, and condition-specific management to support a healthier, more productive workforce.